No significant difference of the bleeding rate was observed between the clipping and nonclipping groups, regardless of the size of the lesions.
Significant correlations between VWF Ag and bleed rate and also between age and bleed rate were observed.
Higher 30-day mortality rates were observed in bleeding vs non-bleeding patients (68% vs 50%, p = 0.19).
Patients in the diode laser group were at higher risk for bleeding; however, the blood transfusion rate and check bleeding rate were not significantly higher than those observed in the other groups (P>0.05).
On the other side observed coagulation ratios in included studies with veno-venous ECMO were inferior to those attained in previously reported veno-arterial ECMO patients (mean = 1.45 vs 1.64) [12]; however, no association between coagulation ratio and increased bleeding rates could be observed in our results with veno-venous ECMO patients.
Serious bleeding rates were consistent with those observed in previous studies throughout the 6-day treatment period, and prophylactic heparin did not increase the risk for serious bleeding compared with placebo (2.3%and2.5%5%, respectively), including CNS bleeding (0.3% in both arms).
The hospitalisation rate for peptic ulcer bleeding was stable during the study period, although a higher rate was observed in men than in women (figure 1).
Compared with warfarin (0.82 %), the low-dose edoxaban group had a significantly lower rate of gastrointestinal bleeding (1.23 %; p < 0.001 vs. warfarin), while a statistically higher rate was observed in the high-dose edoxaban group (1.51 %; p = 0.03 vs. warfarin).
Analogous bleeding rates were 11.0, 23.9, and 66.2, respectively, among low (n=728), intermediate (n=634), and high (n=135) bleeding risk patients.
Major bleeding rates were available in all studies (n=32 287).
